Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Written by ACN Newswire

Wednesday, 1 August 2018, 18:35 HKT/SGT

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.

Topic: Press release summarySectors: Daily Finance, Daily News, BioTech ^[1]^[2]^[3] http://www.acnnewswire.com From the Asia Corporate News Network

References

^{^} Daily Finance (www.acnnewswire.com)
^{^} Daily News (www.acnnewswire.com)
^{^} BioTech (www.acnnewswire.com)

Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

References

Passing on a family business isn’t easy. Here’s why – and what factors predict success

A global tax crackdown is coming for crypto – including NZ trades worth billions

Many super funds are still failing retirees, even as millions prepare to stop work

How to respond to sexual harassment or assault at a work party

China reportedly wants to do more deals in its own currency. Australia’s banks aren’t ready

Here’s what new debt-to-income home loan caps mean for banks and borrowers

Traditions of Rural Bali at Villa Sabana

Essential Reasons to Opt for a Professional Valuation Before Selling Your Commercial Property

Why family violence leave should be paid

41% of full-time and 35% of part-time jobs can be done from home

DesignStreet marks 27 years with a bold rebrand

Controlling business spend is helping finance leaders to forecast with confidence

From correction to resilience: making the most of Australia’s evolving insurance landscape

AI is Changing Trademarking Forever

Times Media Australia Launches Times Australia Today

The Future of Ozi.com.au

Brisbane’s brightest recognised: Daniel Mikus and James Rolph win Specialist Services Award at the 2025 Brisbane Young Entrepreneur Awards - again

How Contiki is Redefining Travel for Young Adventurers

Navigating the Cosmetic Advertising Crackdown Before September Guidelines Hit

Defining Actionable AI for Australian IT Efficiency and Security